SPRY

ARS Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

17.870

-0.05(-0.279%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

18.050

Open

17.870

VWAP

17.75

Vol

2.73M

Mkt Cap

1.76B

Low

17.410

Amount

48.42M

EV/EBITDA(TTM)

Total Shares

96.90M

1.48B

EV/OCF(TTM)

P/S(TTM)

18.96

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

12.92M

+2484.33%

26.91M

+1201.27%

Estimates Revision

The market is revising Downward the revenue expectations for ARS Pharmaceuticals, Inc. (SPRY) for FY2025, with the revenue forecasts being adjusted by -10.07% over the past three months. During the same period, the stock price has changed by 26.38%.

Revenue Estimates for FY2025

Revise Downward

-10.07%

In Past 3 Month

Stock Price

Go Up

+26.38%

In Past 3 Month

4 Analyst Rating

67.88% Upside

Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 30.00 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

67.88% Upside

Current: 17.870

Low

28.00

Averages

30.00

High

32.00

67.88% Upside

Current: 17.870

Low

28.00

Averages

30.00

High

32.00

Scotiabank

Louise Chen

Buy

Initiates

$30

2025-03-07

Reason

Scotiabank

Louise Chen

Price Target

$30

2025-03-07

Initiates

Buy

Reason

Raymond James

Ryan Deschner

Strong Buy

Maintains

$26 → $28

2025-01-14

Reason

Raymond James

Ryan Deschner

Price Target

$26 → $28

2025-01-14

Maintains

Strong Buy

Reason

Leerink Partners

Roanna Ruiz

Buy

Maintains

$26 → $27

2025-01-13

Reason

Leerink Partners

Roanna Ruiz

Price Target

$26 → $27

2025-01-13

Maintains

Buy

Reason

Cantor Fitzgerald

Josh Schimmer

Buy

Reiterates

$30

2024-10-08

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$30

2024-10-08

Reiterates

Buy

Reason

Leerink Partners

Roanna Ruiz

Buy

Maintains

$21 → $25

2024-09-20

Reason

Leerink Partners

Roanna Ruiz

Price Target

$21 → $25

2024-09-20

Maintains

Buy

Reason

Cantor Fitzgerald

Josh Schimmer

Buy

Reiterates

$30

2024-09-16

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$30

2024-09-16

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for ARS Pharmaceuticals Inc (SPRY.O) is -12.31, compared to its 5-year average forward P/E of -12.08. For a more detailed relative valuation and DCF analysis to assess ARS Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.08

Current PE

-12.31

Overvalued PE

-7.66

Undervalued PE

-16.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.52

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.22

Undervalued EV/EBITDA

-5.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6728.27

Current PS

17.92

Overvalued PS

27684.16

Undervalued PS

-14227.62

Financials

Annual

Quarterly

FY2025Q1

7.97M

Total Revenue

FY2025Q1

YoY :

+181.81%

-37.18M

Operating Profit

FY2025Q1

YoY :

+229.77%

-33.94M

Net Income after Tax

FY2025Q1

YoY :

+218.18%

-0.35

EPS - Diluted

FY2025Q1

YoY :

+501.10%

-40.83M

Free Cash Flow

FY2025Q1

86.28

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

-21.68

FCF Margin - %

FY2025Q1

-425.69

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

18.0M

USD

3-6

Months

1.9M

USD

6-9

Months

30.8M

USD

0-12

Months

43.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 326% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

563.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.1M

Volume

Months

6-9

500.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

18.0M

USD

3-6

Months

1.9M

USD

6-9

Months

30.8M

USD

0-12

Months

43.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SPRY News & Events

Events Timeline

2025-07-18 (ET)

2025-07-18

09:27:21

ARS Pharmaceuticals announces UK MHRA approval of EURneffy

2025-05-14 (ET)

2025-05-14

07:12:23

ARS Pharmaceuticals reports Q1 EPS (35c), consensus (36c)

2025-05-07 (ET)

2025-05-07

08:14:35

ARS Pharmaceuticals' neffy 1mg now available across U.S.

News

9.0

07-18Newsfilter

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

6.5

06-12Benzinga

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs

1.0

05-27Newsfilter

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

People Also Watch

Spyre Therapeutics Inc

New Mountain Finance Corp

BioLife Solutions Inc

Easterly Government Properties Inc

Alpha and Omega Semiconductor Ltd

American Woodmark Corp

Cracker Barrel Old Country Store Inc

FAQ

What is ARS Pharmaceuticals Inc (SPRY) stock price today?

The current price of SPRY is 17.87 USD — it has decreased -0.28 % in the last trading day.

SPRY

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SPRY News & Events

Events Timeline

News

People Also Watch

FAQ

What is ARS Pharmaceuticals Inc (SPRY) stock price today?

What is ARS Pharmaceuticals Inc (SPRY)'s business?

What is the price predicton of SPRY Stock?

What is ARS Pharmaceuticals Inc (SPRY)'s revenue for the last quarter?

What is ARS Pharmaceuticals Inc (SPRY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ARS Pharmaceuticals Inc (SPRY)'s fundamentals?

How many employees does ARS Pharmaceuticals Inc (SPRY). have?

What is ARS Pharmaceuticals Inc (SPRY) market cap?